文献速递神经肌肉病

感觉神经元作为多聚谷氨酰胺扩展ATXN3小鼠周围神经病治疗靶点

Establishing Sensory Neurons as Therapeutic Targets in Peripheral Neuropathy Driven by Polyglutamine Expanded Murine ATXN3.
PubMed 文献 · Ann Neurol · 2026-07-31

该研究在SCA3敲入与敲除小鼠中开展感觉运动神经传导与行为学检测,发现敲入小鼠出现进行性感觉运动缺陷、周围组织病理及RNA剪接失调,而敲除小鼠周围神经功能正常;在感觉神经元特异性沉默突变ATXN3后,周围神经异常与背根神经节剪接失调显著改善。

要点

  • SCA3敲入小鼠出现进行性感觉运动缺陷与周围神经病理,提示突变ATXN3的毒性获得性功能驱动周围神经病。
  • 敲除小鼠周围神经功能正常,支持突变ATXN3而非ATXN3缺失是致病驱动因素。
  • 感觉神经元特异性沉默突变ATXN3可改善周围神经异常与DRG剪接失调,提示感觉神经元为治疗靶点。

核心结论

  • 突变ATXN3的毒性获得性功能驱动SCA3周围神经变性,感觉神经元是SCA3及相关重复扩增疾病周围干预的关键治疗靶点。

研究设计与样本

  • 研究采用SCA3敲入Atxn3Q300/Q6小鼠与Atxn3-/-敲除小鼠,进行感觉运动神经传导与行为学检测,并用bulk RNA测序评估敲入小鼠背根神经节转录变化。
  • 研究构建条件性「OFF」SCA3敲入小鼠并与Avil-Cre杂交,以在感觉神经元中选择性沉默突变ATXN3,随后重复周围表型检测。

主要发现

  • 敲入小鼠出现进行性感觉运动缺陷、周围组织病理与RNA剪接失调,与SCA3临床特征平行。
  • 敲除小鼠周围神经功能正常,提示突变ATXN3的毒性获得性功能是致病驱动因素。
  • 感觉神经元特异性沉默突变ATXN3显著改善周围神经异常与DRG剪接失调。

临床怎么用

  • 在SCA3及相关重复扩增疾病中,应关注周围神经受累评估,并将感觉神经元作为周围干预的潜在靶点。
  • 该条件性「OFF」敲入小鼠平台可用于临床前开发针对SCA3周围神经病的干预措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Repeat expansion mutations underlie diverse neurogenetic disorders, many involving the peripheral nervous system. Despite peripheral neuropathy being the most common neurological disorder worldwide, its contribution to repeat expansion diseases remains poorly defined, and robust preclinical models are limited. We established a translational framework to study peripheral neuropathy in spinocerebellar ataxia type 3 (SCA3), a fatal multisystem disorder caused by a pathogenic CAG expansion in ATXN3. METHODS: SCA3 Knock-In Atxn3Q300/Q6 (KI) and Atxn3-/- Knock-Out (KO) mice underwent sensorimotor nerve conduction and behavioral testing. Peripheral tissues were evaluated for SCA3-related pathology, and transcriptional changes in KI dorsal root ganglia (DRG) were assessed by bulk RNA sequencing. To test therapeutic relevance, we generated a conditional "OFF" SCA3 knock-in (cKI) mouse and crossed it with Avil-Cre to selectively silence mutant ATXN3 in sensory neurons. Peripheral phenotyping was repeated in Avil-Cre; cKI mice. RESULTS: KI mice developed progressive sensorimotor deficits, peripheral histopathology, and RNA splicing dysregulation that parallel clinical features of SCA3. In contrast, KO mice showed normal peripheral nerve function, implicating toxic gain-of-function from mutant ATXN3 as the causative driver. Sensory neuron-specific silencing of mutant ATXN3 significantly ameliorated peripheral nerve abnormalities and DRG splicing dysregulation. INTERPRETATION: These findings define a pathogenic role for repeat expansion-driven peripheral nerve degeneration in SCA3, identify sensory neurons as key therapeutic targets, and provide a preclinical platform for developing peripheral interventions in SCA3 and related repeat expansion disorders. ANN NEUROL 2026;100:1039-1054.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Mato JP, Hayes JM, Emerson J, et al. Establishing Sensory Neurons as Therapeutic Targets in Peripheral Neuropathy Driven by Polyglutamine Expanded Murine ATXN3. Ann Neurol. 2026. PMID: 42538636. doi:10.1002/ana.78317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。